ReviewDiscoveries (Craiova, Romania)
Complexities of Dengue Fever: Pathogenesis, Clinical Features and Management Strategies.
Review in Discoveries (Craiova, Romania). The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Dengue in deployed military personnel, 1905-2024: a systematic review of incidence, diagnostics and prevention.Journal of travel medicine · 2026Pooled it
- Dengue Vodcast: Insights from Recent Infectious Disease Congresses.Infectious diseases and therapy · 2026Review
- Epidemiological Trends and Clinical Profile of Dengue in Assam: A Retrospective Analysis From 2022 to 2025.Cureus · 2026Article
- Clinical profile and predictors of adverse outcomes in pediatric dengue fever presenting with febrile illness: a prospective observational study in Burao, Somaliland.Frontiers in pediatrics · 2026Article
- Europe Faces Multiple Arboviral Threats in 2025.Viruses · 2025Review
- Clinical features and laboratory indicators of dengue infection in China: a retrospective study of adult patients in a hospital of traditional Chinese medicine.Frontiers in medicine · 2025Article
- Early diagnostic value of dengue virus NS1 antigen and nucleic acid testing.American journal of translational research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Dengue fever, transmitted through the bite of infected Aedes mosquitos, poses a significant global threat, particularly in the tropical and subtropical region. In this review, we aim to summarize the existent literature on dengue virus infection and to enlighten the reader on recent advances and knowledge. Dengue virus infection can cause a spectrum of clinical manifestations, ranging from asymptomatic or mild illness to more severe and potentially life-threatening complications. Pathogenesis of dengue is based on viral and host factors. Viral factors include NS1 antigen and genomic factors. Host factors include antibody dependent enhancement, anti-NS1 antibodies, cytokines, cross reactive T-Cell response, HLA allele variation and non-HLA mediated polymorphisms. The clinical picture of dengue is described on the basis of WHO 1997 and 2009 criteria. It is classified into dengue fever, dengue hemorrhagic fever (DHF), and dengue shock syndrome (DSS). Life-threatening complications can develop in severe cases, and this includes renal complications such as acute kidney injury (AKI) and hepatic complications such as hepatic dysfunction and in rare cases, fulminant hepatic failure. Neurological complications, cardiac complications and respiratory distress syndrome have also been reported. Treatment methods include targeting the dengue vector and Carica papaya, a natural remedy with antiviral properties. Additionally, the role of corticosteroids, intravenous immunoglobulins, and mast cell inhibitors has been explored in dengue treatment, aiming to reduce severity. Novel approaches involve drugs targeting dengue proteins and host factors necessary for the virus's life cycle, offering potential avenues for more targeted therapeutic interventions. In recent years, significant progress has been made in the development of vaccines against dengue, with Sanofi Pasteur's Dengvaxia being the first licensed vaccine approved for use. Utilizing various approaches such as recombinant proteins, viral vectors and viral like particles, various alternatives have been provided which aim to be safer substitutes to Dengvaxia while maintaining the effectiveness. A review on dengue is essential for clinicians and healthcare professionals to stay updated on diagnostics, treatment protocols and prevention strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.